These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 17438184)

  • 1. Cosmetic permanent fillers for soft tissue augmentation: a new contraindication for interferon therapies.
    Fischer J; Metzler G; Schaller M
    Arch Dermatol; 2007 Apr; 143(4):507-10. PubMed ID: 17438184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sarcoid granulomas in facial cosmetic filler material: induction by interferon-α and ribavirin in a patient with hepatitis C].
    López-Pestaña A; Tuneu A; Lobo C; Zubizarreta J
    Actas Dermosifiliogr; 2011 Nov; 102(9):746-7. PubMed ID: 21640959
    [No Abstract]   [Full Text] [Related]  

  • 3. Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases.
    Descamps V; Landry J; Francès C; Marinho E; Ratziu V; Chosidow O
    Dermatology; 2008; 217(1):81-4. PubMed ID: 18446029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
    Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
    J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
    Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
    Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 9. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T; Farkas A; Tolvaj G; Horváth G
    Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection].
    Lee MY; Cho H; Kim YM; Lee JS
    Korean J Hepatol; 2006 Sep; 12(3):444-8. PubMed ID: 16998297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cutaneous sarcoidosis during pegylated interferon alpha and ribavirin treatment of chronic hepatitis C--a case report].
    Honsová E; Sticová E; Sperl J
    Cesk Patol; 2007 Jan; 43(1):27-30. PubMed ID: 17370474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcoidosis or foreign-body granulomatous reaction during interferon treatment?
    Bitetto D; Fumolo E; Fabris C; Toniutto P
    Liver Int; 2010 Aug; 30(7):1083-4; author reply 1084. PubMed ID: 20214737
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 15. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Onyike CU; Bonner JO; Lyketsos CG; Treisman GJ
    Am J Psychiatry; 2004 Mar; 161(3):429-35. PubMed ID: 14992966
    [No Abstract]   [Full Text] [Related]  

  • 16. [Antiviral therapy for chronic viral hepatitis B and C].
    Iino S
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():787-91. PubMed ID: 12722317
    [No Abstract]   [Full Text] [Related]  

  • 17. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.
    Wirth S; Pieper-Boustani H; Lang T; Ballauff A; Kullmer U; Gerner P; Wintermeyer P; Jenke A
    Hepatology; 2005 May; 41(5):1013-8. PubMed ID: 15793840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatitis C infection. Overweight virus carriers are more difficult to cure].
    MMW Fortschr Med; 2004 Mar; 146(13):58. PubMed ID: 15219135
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
    Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.